Stakeholders seek flexibility, greater harmonization in FDA human subject protection rules
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesClinical TrialsMedical DevicesNorth AmericaPharmaceuticalsRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesClinical TrialsMedical DevicesNorth AmericaPharmaceuticals